Abstracts Archive - Page 148 of 1683 - ATC Abstracts

2022 American Transplant Congress
Surveillance of Donor-Derived Cell-Free DNA Throughout Treatment of Acute Rejection in Pediatric Renal Transplant Recipients
K. A. Klein¹, E. L. Kincaide¹, M. Fei², A. M. Bell², M. Y. Arar³, D. Ranch³
¹Pharmacotherapy Education and Research Center, UT Health San Antonio, San Antonio, TX, ²CareDx, Inc., Brisbane, CA, ³Long School of Medicine, UT Health San Antonio, San Antonio, TX
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is a dynamic plasma biomarker for allograft rejection with limited data in pediatric renal transplant recipients and few reports describing…
2022 American Transplant Congress
25 Years of a Standardized Living Donor (LD) Intestinal Transplant Technique – What Has Been Achieved?
R. Gruessner¹, A. C. Gruessner²
¹SUNY Downstate Medical Center, Brooklyn, NY, ²SUNY Downstate Medical Center, Brooklyn, MA
*Purpose: The indication for intestinal transplantation (ITX) is irreversible intestinal failure with dependence on total parenteral nutrition (TPN). Most intestinal transplants are from deceased donors…
2022 American Transplant Congress
Outcomes in Pediatric Intestinal Retransplantation
E. J. Lee¹, G. Mazariegos¹, K. Soltys¹, G. Bond¹, A. Ganoza¹, J. Rudolph², S. Horslen², R. Sindhi¹, A. Khanna¹
¹Transplant Surgery, UPMC, Pittsburgh, PA, ²Division of Gastroenterology, Hepatology and Nutrition,, UPMC, Pittsburgh, PA
*Purpose: Historically, intestinal retransplantation (Re-ITx) has been associated with high morbidity and mortality.*Methods: Retrospective chart review of patients who underwent Re-ITx at our institution between…
2022 American Transplant Congress
Enhanced Delivery of Nanomedicine to Human Kidney During Ex Vivo Perfusion
C. Albert¹, L. Bracaglia¹, A. Koide², J. R. DiRito¹, T. Lysyy¹, E. Christopher¹, J. Grundler¹, J. T. Langford¹, D. Haakinson¹, J. S. Pober¹, W. M. Saltzman¹, S. Koide², G. Tietjen¹
¹Yale University, new haven, CT, ²Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY
*Purpose: An efficient delivery of therapeutic agents to graft endothelial cells (ECs) prior to transplantation could render organs more resistant to injury, improving clinical outcomes…
2022 American Transplant Congress
Optimizing Multimodal Pain Control Post Laparoscopic Living Donor Nephrectomy
J. Francois Whitt¹, A. Centeno¹, T. Harrison¹, P. Cabrera¹, S. Zahid¹, L. Chen²
¹Jackson Memorial Hospital, Miami, FL, ²University of Miami/Jackson Memorial Hospital, Miami, FL
*Purpose: The purpose of this study is to examine the use of a multimodal pain regimen in our diverse population to better characterize short and…
2022 American Transplant Congress
Single Center Experience with Acute Kidney Injury Deceased Donor Kidneys from Marginal Donors
B. K. Sharda, M. Garner, A. Farney, G. Orlando, C. Jay, J. Rogers, A. Daniel, A. Gutierrez, N. Sakhovskaya, R. Stratta
Atrium Health Wake Forest Baptist Medical Center, Winston Salem, NC
*Purpose: Many centers will selectively transplant kidneys from standard criteria donors (SCD) with terminal acute kidney injury (AKI). However, there is limited experience with transplanting…
2022 American Transplant Congress
Outcomes of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant Recipients
T. S. Mahmoud¹, J. Yagan¹, A. Hasan², O. Gheith¹, M. Mostafa¹, S. Rida¹, N. El-Serwy¹, M. Shaker¹, M. Khalid¹, P. Nair¹, T. Alotaibi¹
¹Nephrology, Organ Transplant Center, Kuwait, Kuwait, ²Immunometabolism, Dasman Diabetes Center, Kuwait, Kuwait
*Purpose: The impact of the new glucose lowering therapies, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and Glucagon-like peptide-1 receptor agonists (GLP-1RA), on managing patients with type…
2022 American Transplant Congress
CoVID-19 Vaccine Efficacy in Heart Transplant Recipients, a Single Center Experience
M. Yu¹, S. B. Sharmin², C. Joyce³, Z. Pieters¹, S. DeSirkar¹, M. Thomas¹, S. Kim¹, E. Bruno¹, M. Liebo¹, A. Heroux⁴, N. Clark¹, G. Reid¹, S. Uprichard²
¹Loyola University Medical Center, Maywood, IL, ²Microbiology and Immunology, Loyola University Chicago, Chicago, IL, ³Department of Public Health Sciences, Loyola University Chicago, Chicago, IL, ⁴Loyola Univ Medical Ctr, Maywood, IL
*Purpose: Transplant recipients have worse CoVID-19 survival compared to the general population, and thus are recommended to be vaccinated and boosted. Determinants of vaccination efficacy…
2022 American Transplant Congress
Locoregional Therapy and Long-Term Post-Transplant Outcomes for HCC Liver Transplant Recipients
T. Ishaque, S. R. Weeks, A. Kolarich, J. Ruck, J. Garonzik-Wang, D. Segev, A. Massie, B. King
Johns Hopkins Medical Institutions, Baltimore, MD
*Purpose: In last decade, locoregional therapy (LRT) have been widely used to downstage HCC patients in order to qualify for liver transplantation. Large-scale direct comparisons…
2022 American Transplant Congress
Immunosuppressant Medications Use in Patients with Transplant Failure: A Canadian Multi-Centre Prospective Study
G. Knoll¹, M. Chassé², D. Fergusson³, A. A. House⁴, O. Johnston⁵, R. Mainra⁶, D. Baran⁷, D. Treleaven⁸, l. senecal⁹, L. Tibbles¹⁰, M. Hebert¹¹, M. Karpinski¹², T. Campbell¹³, T. Ramsay¹⁴, J. Kim¹⁵, I. Houde¹⁶, C. White¹⁷, J. Perl¹⁵, P. Karnabi¹⁸, J. Gill⁵
¹Nephrology, Ottawa Hospital Research Institute, Ottawa, ON, Canada, ²University of Montreal, Montreal, QC, Canada, ³Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁴Nephrology, Western University, London, ON, Canada, ⁵Nephrology, University of British Columbia, Vancouver, BC, Canada, ⁶Nephrology, University of Saskatchewan, Saskatoon, SK, Canada, ⁷Nephrology, McGill University, Montreal, QC, Canada, ⁸Nephrology, McMaster University, Hamilton, ON, Canada, ⁹Nephrology, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada, ¹⁰Nephrology, University of Calgary, Calgary, AB, Canada, ¹¹Nephrology, University of Montreal, Montreal, QC, Canada, ¹²Nephrology, University of Manitoba, Winnipeg, MB, Canada, ¹³University of Alberta, Alberta, AB, Canada, ¹⁴Ottawa Hospital Research Institute, Ottawa, ON, Canada, ¹⁵University of Toronto, Toronto, ON, Canada, ¹⁶Laval University, Que´bec, QC, Canada, ¹⁷Queen's University, Kingston, ON, Canada, ¹⁸Ottawa Health Research Institute, Ottawa, ON, Canada
*Purpose: This prospective study determined the association of immunosuppressant medication use with the outcomes of death, hospitalized infection, rejection of the failed allograft, and panel…